{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:53:00Z","timestamp":1778615580852,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T00:00:00Z","timestamp":1518134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T00:00:00Z","timestamp":1518134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>An increased level of brain amyloid deposition and a decreased level of cerebral spinal fluid (CSF) A\u03b242 are currently considered reliable biomarkers of Alzheimer\u2019s disease (AD); however, the usefulness of plasma A\u03b2 levels are not well-established. This study investigated the relationships between plasma A\u03b2 levels and cerebral amyloidosis in 36 non-demented patients with major depressive disorder (MDD). All participants underwent <jats:sup>18<\/jats:sup>F-florbetapir PET imaging and provided a blood sample at the same time for immunomagnetic reduction assay to measure the plasma levels of A\u03b240 and A\u03b242. We found inverse associations of the plasma A\u03b242 level and the A\u03b242\/A\u03b240 ratio, and a positive association of the plasma A\u03b240 level, with cerebral amyloid deposition in the precuneus, parietal and posterior cingulate cortex. Subgroup analyses in subjects with higher <jats:sup>18<\/jats:sup>F-florbetapir uptake values or MDD with amnestic mild cognitive impairment revealed more pervasive relationships of plasma A\u03b2 measures with <jats:sup>18<\/jats:sup>F-florbetapir binding across the brain regions examined. The study suggested that regional brain amyloid deposition in terms of <jats:sup>18<\/jats:sup>F-florbetapir PET uptake had weak-to-moderate associations with plasma A\u03b242 and A\u03b240 levels, and the A\u03b242\/A\u03b240 ratio. Validation in a larger population of subjects of known cerebral amyloidosis status is needed. Careful interpretation of plasma data is warranted.<\/jats:p>","DOI":"10.1038\/s41598-018-21140-3","type":"journal-article","created":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T12:39:53Z","timestamp":1517834393000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Plasma A\u03b2 analysis using magnetically-labeled immunoassays and PET 18F-florbetapir binding in non-demented patients with major depressive disorder"],"prefix":"10.1038","volume":"8","author":[{"given":"Kuan-Yi","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ing-Tsung","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Hsiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Yih","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Lung","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Yao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzu-Chen","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1933-4564","authenticated-orcid":false,"given":"Kun-Ju","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,9]]},"reference":[{"key":"21140_CR1","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/S1474-4422(10)70223-4","volume":"9","author":"B Dubois","year":"2010","unstructured":"Dubois, B. et al. Revising the definition of Alzheimer\u2019s disease: a new lexicon. The Lancet Neurology 9, 1118\u20131127 (2010).","journal-title":"The Lancet Neurology"},{"key":"21140_CR2","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","volume":"6","author":"B Dubois","year":"2007","unstructured":"Dubois, B. et al. Research criteria for the diagnosis of Alzheimer\u2019s disease: revising the NINCDS\u2013ADRDA criteria. The Lancet Neurology 6, 734\u2013746 (2007).","journal-title":"The Lancet Neurology"},{"key":"21140_CR3","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois, B. et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. The Lancet Neurology 13, 614\u2013629 (2014).","journal-title":"The Lancet Neurology"},{"key":"21140_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia 7, 263\u2013269 (2011).","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"21140_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1212\/WNL.0b013e3181e7ca82","volume":"75","author":"P Vemuri","year":"2010","unstructured":"Vemuri, P. et al. Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology 75, 143\u2013151 (2010).","journal-title":"Neurology"},{"key":"21140_CR6","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1021\/cn500101j","volume":"5","author":"K-Y Tzen","year":"2014","unstructured":"Tzen, K.-Y. et al. Plasma A\u03b2 but not tau is related to brain PiB retention in early Alzheimer\u2019s disease. ACS chemical neuroscience 5, 830\u2013836 (2014).","journal-title":"ACS chemical neuroscience"},{"key":"21140_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.exger.2009.09.008","volume":"45","author":"A Cedazo-Minguez","year":"2010","unstructured":"Cedazo-Minguez, A. & Winblad, B. Biomarkers for Alzheimer\u2019s disease and other forms of dementia: clinical needs, limitations and future aspects. Experimental Gerontology 45, 5\u201314 (2010).","journal-title":"Experimental Gerontology"},{"key":"21140_CR8","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.2174\/156720512804142967","volume":"9","author":"M Chiu","year":"2012","unstructured":"Chiu, M. et al. New assay for old markers-plasma beta amyloid of mild cognitive impairment and Alzheimer\u2019s disease. Current Alzheimer Research 9, 1142\u20131148 (2012).","journal-title":"Current Alzheimer Research"},{"key":"21140_CR9","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S1474-4422(06)70501-4","volume":"5","author":"M van Oijen","year":"2006","unstructured":"van Oijen, M., Hofman, A., Soares, H. D., Koudstaal, P. J. & Breteler, M. M. Plasma A\u03b2 1\u201340 and A\u03b2 1\u201342 and the risk of dementia: a prospective case-cohort study. The Lancet Neurology 5, 655\u2013660 (2006).","journal-title":"The Lancet Neurology"},{"key":"21140_CR10","doi-asserted-by":"publisher","first-page":"14052","DOI":"10.1073\/pnas.0805902105","volume":"105","author":"N Schupf","year":"2008","unstructured":"Schupf, N. et al. Peripheral A\u03b2 subspecies as risk biomarkers of Alzheimer\u2019s disease. Proceedings of the National Academy of Sciences 105, 14052\u201314057 (2008).","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"21140_CR11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrneurol.2015.119","volume":"11","author":"JM Tarasoff-Conway","year":"2015","unstructured":"Tarasoff-Conway, J. M. et al. Clearance systems in the brain-implications for Alzheimer disease. Nat Rev Neurol 11, 457\u2013470 (2015).","journal-title":"Nat Rev Neurol"},{"key":"21140_CR12","doi-asserted-by":"publisher","first-page":"205031211559825","DOI":"10.1177\/2050312115598250","volume":"3","author":"KB Shanthi","year":"2015","unstructured":"Shanthi, K. B., Krishnan, S. & Rani, P. A systematic review and meta-analysis of plasma amyloid 1-42 and tau as biomarkers for Alzheimer\u2019s disease. SAGE open medicine 3, 2050312115598250 (2015).","journal-title":"SAGE open medicine"},{"key":"21140_CR13","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1109\/TASC.2010.2087304","volume":"21","author":"M Chiu","year":"2011","unstructured":"Chiu, M. et al. Multi-channel squid-based ultra-high-sensitivity in-vitro detections for bio-markers of alzheimer\u2019s disease via immunomagnetic reduction. Applied Superconductivity, IEEE Transactions on 21, 477\u2013480 (2011).","journal-title":"Applied Superconductivity, IEEE Transactions on"},{"key":"21140_CR14","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1177\/1087057110362099","volume":"15","author":"JL Richens","year":"2010","unstructured":"Richens, J. L. et al. Quantitative validation and comparison of multiplex cytokine kits. Journal of biomolecular screening 15, 562\u2013568 (2010).","journal-title":"Journal of biomolecular screening"},{"key":"21140_CR15","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1006\/bbrc.1999.0552","volume":"257","author":"Y-M Kuo","year":"1999","unstructured":"Kuo, Y.-M. et al. High levels of circulating A\u03b242 are sequestered by plasma proteins in Alzheimer\u2019s disease. Biochemical and Biophysical Research Communications 257, 787\u2013791 (1999).","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"21140_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1109\/TNB.2013.2240009","volume":"12","author":"S-Y Yang","year":"2013","unstructured":"Yang, S.-Y. et al. Experimental study on low-detection limit for immunomagnetic reduction assays by manipulating reagent entities. IEEE transactions on nanobioscience 12, 65\u201368 (2013).","journal-title":"IEEE transactions on nanobioscience"},{"key":"21140_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/alzrt163","volume":"5","author":"H Zetterberg","year":"2013","unstructured":"Zetterberg, H. et al. Plasma tau levels in Alzheimer\u2019s disease. Alzheimer\u2019s research & therapy 5, 9 (2013).","journal-title":"Alzheimer\u2019s research & therapy"},{"key":"21140_CR18","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/S0304-8853(98)00580-0","volume":"194","author":"R K\u00f6titz","year":"1999","unstructured":"K\u00f6titz, R., Weitschies, W., Trahms, L., Brewer, W. & Semmler, W. Determination of the binding reaction between avidin and biotin by relaxation measurements of magnetic nanoparticles. Journal of magnetism and magnetic materials 194, 62\u201368 (1999).","journal-title":"Journal of magnetism and magnetic materials"},{"key":"21140_CR19","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1021\/cn200028j","volume":"2","author":"C-C Yang","year":"2011","unstructured":"Yang, C.-C. et al. Biofunctionalized magnetic nanoparticles for specifically detecting biomarkers of Alzheimer\u2019s disease in vitro. ACS chemical neuroscience 2, 500\u2013505 (2011).","journal-title":"ACS chemical neuroscience"},{"key":"21140_CR20","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edn, (2013).","DOI":"10.1176\/appi.books.9780890425596"},{"key":"21140_CR21","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1212\/WNL.24.11.1019","volume":"24","author":"H Buschke","year":"1974","unstructured":"Buschke, H. & Fuld, P. A. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology 24, 1019\u20131019 (1974).","journal-title":"Neurology"},{"key":"21140_CR22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0022-510X(98)00225-1","volume":"160","author":"R-T Lin","year":"1998","unstructured":"Lin, R.-T. et al. Prevalence and subtypes of dementia in southern Taiwan: impact of age, sex, education, and urbanization. Journal of the Neurological Sciences 160, 67\u201375 (1998).","journal-title":"Journal of the Neurological Sciences"},{"key":"21140_CR23","first-page":"762","volume":"95","author":"C Liu","year":"1996","unstructured":"Liu, C. et al. Prevalence of dementia in an urban area in taiwan. Journal of the Formosan Medical Association 95, 762 (1996).","journal-title":"Journal of the Formosan Medical Association"},{"key":"21140_CR24","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1097\/JGP.0b013e318202clc6","volume":"19","author":"Y-C Yeh","year":"2011","unstructured":"Yeh, Y.-C. et al. Subtypes of mild cognitive impairment among the elderly with major depressive disorder in remission. American Journal of Geriatric Psych 19, 923 (2011).","journal-title":"American Journal of Geriatric Psych"},{"key":"21140_CR25","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.apradiso.2010.07.001","volume":"68","author":"C-H Yao","year":"2010","unstructured":"Yao, C.-H. et al. GMP-compliant automated synthesis of [18 F] AV-45 (Florbetapir F 18) for imaging \u03b2-amyloid plaques in human brain. Applied Radiation and Isotopes 68, 2293\u20132297 (2010).","journal-title":"Applied Radiation and Isotopes"},{"key":"21140_CR26","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.nucmedbio.2010.02.003","volume":"37","author":"K-J Lin","year":"2010","unstructured":"Lin, K.-J. et al. Whole-body biodistribution and brain PET imaging with [18F] AV-45, a novel amyloid imaging agent\u2013a pilot study. Nuclear Medicine and Biology 37, 497 (2010).","journal-title":"Nuclear Medicine and Biology"},{"key":"21140_CR27","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1007\/s00259-013-2350-x","volume":"40","author":"T Hsiao","year":"2013","unstructured":"Hsiao, T. et al. Perfusion-like template and standardized normalization-based brain image analysis using 18F-florbetapir (AV-45\/Amyvid) PET. European journal of nuclear medicine and molecular imaging 40, 908\u2013920 (2013).","journal-title":"European journal of nuclear medicine and molecular imaging"},{"key":"21140_CR28","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.2967\/jnumed.109.064360","volume":"50","author":"N Tolboom","year":"2009","unstructured":"Tolboom, N. et al. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. Journal of Nuclear Medicine 50, 1464\u20131470 (2009).","journal-title":"Journal of Nuclear Medicine"},{"key":"21140_CR29","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.neuint.2009.08.006","volume":"55","author":"N Le Bastard","year":"2009","unstructured":"Le Bastard, N. et al. No correlation between time-linked plasma and CSF A\u03b2 levels. Neurochemistry International 55, 820\u2013825 (2009).","journal-title":"Neurochemistry International"},{"key":"21140_CR30","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1001\/archneur.57.1.100","volume":"57","author":"PD Mehta","year":"2000","unstructured":"Mehta, P. D. et al. Plasma and cerebrospinal fluid levels of amyloid \u03b2 proteins 1\u201340 and 1\u201342 in Alzheimer disease. Archives of Neurology 57, 100\u2013105 (2000).","journal-title":"Archives of Neurology"},{"key":"21140_CR31","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3233\/JAD-2010-091606","volume":"20","author":"IA van Rossum","year":"2010","unstructured":"van Rossum, I. A., Vos, S., Handels, R. & Visser, P. J. Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. Journal of Alzheimer\u2019s Disease 20, 881\u2013891 (2010).","journal-title":"Journal of Alzheimer\u2019s Disease"},{"key":"21140_CR32","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/emmm.200900048","volume":"1","author":"AM Fagan","year":"2009","unstructured":"Fagan, A. M. et al. Cerebrospinal fluid tau and ptau 181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer9s disease. EMBO molecular medicine 1, 371\u2013380 (2009).","journal-title":"EMBO molecular medicine"},{"key":"21140_CR33","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.3233\/JAD-2010-090249","volume":"20","author":"JK Lui","year":"2010","unstructured":"Lui, J. K. et al. Plasma amyloid-\u03b2 as a biomarker in Alzheimer\u2019s disease: the AIBL study of aging. Journal of Alzheimer\u2019s Disease 20, 1233\u20131242 (2010).","journal-title":"Journal of Alzheimer\u2019s Disease"},{"key":"21140_CR34","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1212\/01.WNL.0000091890.32140.8F","volume":"61","author":"R Mayeux","year":"2003","unstructured":"Mayeux, R. et al. Plasma A\u03b240 and A\u03b242 and Alzheimer\u2019s disease Relation to age, mortality, and risk. Neurology 61, 1185\u20131190 (2003).","journal-title":"Neurology"},{"key":"21140_CR35","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1001\/archneur.64.3.354","volume":"64","author":"NR Graff-Radford","year":"2007","unstructured":"Graff-Radford, N. R. et al. Association of low plasma A\u03b242\/A\u03b240 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Archives of Neurology 64, 354\u2013362 (2007).","journal-title":"Archives of Neurology"},{"key":"21140_CR36","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1001\/archneurol.2007.57","volume":"65","author":"J Sundel\u00f6f","year":"2008","unstructured":"Sundel\u00f6f, J. et al. Plasma \u03b2 amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Archives of Neurology 65, 256\u2013263 (2008).","journal-title":"Archives of Neurology"},{"key":"21140_CR37","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1212\/WNL.0b013e3181b78448","volume":"73","author":"J-C Lambert","year":"2009","unstructured":"Lambert, J.-C. et al. Association of plasma amyloid \u03b2 with risk of dementia The prospective Three-City Study. Neurology 73, 847\u2013853 (2009).","journal-title":"Neurology"},{"key":"21140_CR38","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1021\/cn400129p","volume":"4","author":"M-J Chiu","year":"2013","unstructured":"Chiu, M.-J. et al. Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer\u2019s disease. ACS chemical neuroscience 4, 1530\u20131536 (2013).","journal-title":"ACS chemical neuroscience"},{"key":"21140_CR39","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1212\/WNL.0b013e318224afb7","volume":"77","author":"D Devanand","year":"2011","unstructured":"Devanand, D. et al. Plasma A\u03b2 and PET PiB binding are inversely related in mild cognitive impairment. Neurology 77, 125\u2013131 (2011).","journal-title":"Neurology"},{"key":"21140_CR40","doi-asserted-by":"crossref","unstructured":"Ovod, V. et al. Amyloid \u03b2 concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimer\u2019s & Dementia (2017).","DOI":"10.1016\/j.jalz.2017.06.2266"},{"key":"21140_CR41","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1001\/archpsyc.63.5.530","volume":"63","author":"RL Ownby","year":"2006","unstructured":"Ownby, R. L. et al. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Archives of General Psychiatry 63, 530\u2013538 (2006).","journal-title":"Archives of General Psychiatry"},{"key":"21140_CR42","doi-asserted-by":"crossref","first-page":"345","DOI":"10.31887\/DCNS.2008.10.3\/mabutters","volume":"10","author":"MA Butters","year":"2008","unstructured":"Butters, M. A. et al. Pathways linking late-life depression to persistent cognitive impairment and dementia. Dialogues in Clinical Neuroscience 10, 345\u2013357 (2008).","journal-title":"Dialogues in Clinical Neuroscience"},{"key":"21140_CR43","doi-asserted-by":"crossref","unstructured":"Tateno, A. et al. Amyloid imaging with [18F] florbetapir in geriatric depression: early\u2010onset versus late\u2010onset. International Journal of Geriatric Psychiatry (2014).","DOI":"10.1002\/gps.4215"},{"key":"21140_CR44","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.neurobiolaging.2012.06.014","volume":"34","author":"RA Sperling","year":"2013","unstructured":"Sperling, R. A. et al. Amyloid deposition detected with florbetapir F 18 (18 F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiology of Aging 34, 822\u2013831 (2013).","journal-title":"Neurobiology of Aging"},{"key":"21140_CR45","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.jagp.2012.11.016","volume":"21","author":"PB Rosenberg","year":"2013","unstructured":"Rosenberg, P. B. et al. Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18 (AV-45) positron emission tomography. The American Journal of Geriatric Psychiatry 21, 272\u2013278 (2013).","journal-title":"The American Journal of Geriatric Psychiatry"},{"key":"21140_CR46","doi-asserted-by":"crossref","unstructured":"Wu, K.-Y. et al. Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: 18F-florbetapir (AV-45\/Amyvid) PET study. European journal of nuclear medicine and molecular imaging, 1\u201310 (2016).","DOI":"10.1007\/s00259-015-3291-3"},{"key":"21140_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-017-0273-4","volume":"7","author":"P Li","year":"2017","unstructured":"Li, P. et al. Beta-amyloid deposition in patients with major depressive disorder with differing levels of treatment resistance: a pilot study. EJNMMI research 7, 24 (2017).","journal-title":"EJNMMI research"},{"key":"21140_CR48","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2967\/jnumed.109.069088","volume":"51","author":"DF Wong","year":"2010","unstructured":"Wong, D. F. et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (flobetapir F 18). Journal of Nuclear Medicine 51, 913\u2013920 (2010).","journal-title":"Journal of Nuclear Medicine"},{"key":"21140_CR49","doi-asserted-by":"publisher","first-page":"e58974","DOI":"10.1371\/journal.pone.0058974","volume":"8","author":"K-L Huang","year":"2013","unstructured":"Huang, K.-L. et al. Regional Amyloid Deposition in Amnestic Mild Cognitive Impairment and Alzheimer\u2019s Disease Evaluated by [18F] AV-45 Positron Emission Tomography in Chinese Population. PLOS ONE 8, e58974 (2013).","journal-title":"PLOS ONE"},{"key":"21140_CR50","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1007\/s00259-016-3359-8","volume":"43","author":"KJ Lin","year":"2016","unstructured":"Lin, K. J. et al. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45\/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer\u2019s disease and mild cognitive impairment. Eur J Nucl Med Mol Imaging 43, 1304\u20131314 (2016).","journal-title":"Eur J Nucl Med Mol Imaging"}],"updated-by":[{"DOI":"10.1038\/s41598-019-43800-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21140-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21140-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21140-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T02:20:36Z","timestamp":1671589236000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21140-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,9]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["21140"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-21140-3","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-019-43800-8","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,9]]},"assertion":[{"value":"20 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"2739"}}